title: Bronchopulmonary segmental lavage with Surfaxin (KL(4)-surfactant) for acute respiratory distress syndrome.
abstract: We performed a trial to assess the safety and tolerability of sequential bronchopulmonary segmental lavage with a dilute synthetic surfactant (Surfaxin) in 12 adults with ARDS. Patients received one of three dosing regimens in which aliquots of Surfaxin were administered via a wedged bronchoscope to each of the 19 bronchopulmonary segments. Suctioning was performed 10-30 s after instillation of individual aliquots. Group 1 patients (n = 3) received one 30-ml aliquot of a 2.5-mg/ml concentration of Surfaxin in each segment, followed by a second 30-ml aliquot with a 10-mg/ml concentration. Group 2 patients (n = 4) received two 30-ml aliquots of the 2.5-mg/ml concentration followed by a third lavage with the 10-mg/ml concentration. Group 3 patients (n = 5) received therapy identical to that received by patients in Group 2 and were eligible for repeat dosing 6 to 24 h later. All patients tolerated the procedure. There were no serious adverse experiences ascribed to either the procedure or the surfactant. In the 96 h after treatment initiation, FI(O(2)) decreased from 0.80 to 0.52 and PEEP decreased from 10.3 to 7.6 cm H(2)O. Bronchoscopic "cleansing" of the lungs with dilute Surfaxin may offer a safe and feasible approach to improving outcomes in patients with ARDS. Wiswell TE, Smith RM, Katz LB, Mastroianni L, Wong DY, Willms D, Heard S, Wilson M, Hite RD, Anzueto A, Revak SD, Cochrane CG. Bronchopulmonary segmental lavage with Surfaxin (KL(4)-surfactant) for acute respiratory distress syndrome.
authors.affiliation: Discovery Laboratories, Doylestown, Pennsylvania, USA. Thomas.Wiswell@mail.tju.edu
authors.forename: T E
authors.initials: TE
authors.lastname: Wiswell
authors.forename: R M
authors.initials: RM
authors.lastname: Smith
authors.forename: L B
authors.initials: LB
authors.lastname: Katz
authors.forename: L
authors.initials: L
authors.lastname: Mastroianni
authors.forename: D Y
authors.initials: DY
authors.lastname: Wong
authors.forename: D
authors.initials: D
authors.lastname: Willms
authors.forename: S
authors.initials: S
authors.lastname: Heard
authors.forename: M
authors.initials: M
authors.lastname: Wilson
authors.forename: R D
authors.initials: RD
authors.lastname: Hite
authors.forename: A
authors.initials: A
authors.lastname: Anzueto
authors.forename: S D
authors.initials: SD
authors.lastname: Revak
authors.forename: C G
authors.initials: CG
authors.lastname: Cochrane
mesh_terms: D018893:Bronchoalveolar Lavage; D001992:Bronchoalveolar Lavage Fluid / Q000737:chemistry; D005260:Female; D006801:Humans; D036341:Intercellular Signaling Peptides and Proteins; D008297:Male; D008875:Middle Aged; D010455:Peptides / Q000008:administration & dosage* / Q000009:adverse effects; D011175:Positive-Pressure Respiration; D011506:Proteins / Q000032:analysis; D011659:Pulmonary Gas Exchange / Q000187:drug effects; D011663:Pulmonary Surfactants / Q000008:administration & dosage* / Q000009:adverse effects; D012128:Respiratory Distress Syndrome / Q000378:metabolism / Q000503:physiopathology / Q000628:therapy*
chemical_list: D036341:Intercellular Signaling Peptides and Proteins; C097558:KL4 surfactant; D010455:Peptides; D011506:Proteins; D011663:Pulmonary Surfactants